2020
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos MA, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances 2020, 4: 830-844. PMID: 32126144, PMCID: PMC7065476, DOI: 10.1182/bloodadvances.2019000779.Peer-Reviewed Original ResearchConceptsChemotherapy resistanceMultiple myelomaProteasome inhibitorsDouble-refractory multiple myelomaHigh-risk featuresBulk tumor populationOverexpression of MCL1Whole-exome sequencingRefractory patientsImmunomodulatory agentsDisease progressionSame patientNovel treatmentsPatientsKaryotypic eventsEvolution of subclonesMyeloma cellsDrug resistanceMyelomaNovel targetIMiDsTumor populationGene mutationsNext-generation sequencingTP53 pathway
2019
The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma
Ziccheddu B, Biancon G, De Philippis C, Bagnoli F, Maura F, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos M, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. Blood 2019, 134: 3056. DOI: 10.1182/blood-2019-122197.Peer-Reviewed Original ResearchMultiple myelomaSpeakers bureauProteasome inhibitorsTP53 mutationsAdvisory CommitteeHigh-dose melphalanMedian overall survivalHigh-risk featuresRefractory multiple myelomaTime of transplantHigh-risk lesionsLine of treatmentNext-generation sequencingBulk tumor populationWhole-exome sequencingInfluence of treatmentMCL1 upregulationOverall survivalRefractory casesComplete responseDisease courseMM patientsPrognostic valueImmunomodulatory agentsPathogenetic role